drugset
drugset / Trial / NCT00404001

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

NCT00404001 ↗

Phase 2 Completed 150 enrolled Ironwood Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of MD-0727 in patients with primary hypercholesterolemia.

Timeline

Start
2006-11
Primary completion
—
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MD-0727 Unknown — Oral

Indications

hyperlipidemia